3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
CNS
1
Breast
1
Conditions
Brain Neoplasms
31
Glioblastoma
24
Gliosarcoma
22
Carcinoma, Non-Small-Cell Lung
16
Glioma
12
Astrocytoma
11
Central Nervous System Neoplasms
9
Oligodendroglioma
8
Lung Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
3
Salivary Gland Neoplasms
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Medulloblastoma
3
Esthesioneuroblastoma, Olfactory
3
Colonic Neoplasms
3
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Familial ependymoma
2
Esophageal Neoplasms
2
Ependymoma
2
Diffuse Intrinsic Pontine Glioma
2
Choroid Plexus Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoid Tumor
2
Anus Neoplasms
2
Wilms Tumor
1
Interventions
selpercatinib
2
alectinib
1
Pemetrexed
1
Gefitinib
1
Erlotinib Hydrochloride
1
Carboplatin
1
AZD3759
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
Erlotinib Hydrochloride
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled